AI's near-term value in biotech is orchestration and parallelization, not speed
FinanceYF5 · x · 2026-10-29
Cody argues AI×biotech can indeed help cure diseases, but the biggest near-term opportunity isn't dramatically shortening individual projects — it's orchestration and parallelization. Many drug developers experience only a handful of critical go/no-go decisions in a career, while burning most of their time on email and coordination.
More from Companies & People
- Lean 4-person AI startup Physera hires to build training and eval infra for multimodal coding agents — himanshustwts · 2026-10-29
- Serval CEO on taking on ServiceNow with coding agents for enterprise IT — No Priors · 2026-10-29
- Serval CEO on using coding agents to take on ServiceNow in enterprise IT — No Priors · 2026-10-29
- NYU's Center for Data Science is hiring a new Chair under the new Courant Institute School — LakeBrenden · 2026-10-29
- KUKA bets on physical AI to teach its ~600,000 installed robots new tricks — xmercury_one · 2026-10-29
- Sarvam AI's Indus Cowork goes live for 2,500 Maharashtra officials amid 'mediocre PSU' criticism — pranavmarla · 2026-10-29